Scherrer K, Eans S, Medina J, Senadheera S, Khaliq T, Murray T
Pharmaceuticals (Basel). 2023; 16(9).
PMID: 37765026
PMC: 10535824.
DOI: 10.3390/ph16091218.
Paul A, Woolley K, Rahmatullah M, Wilairatana P, Smith J, Gueven N
Pharmaceuticals (Basel). 2022; 15(7).
PMID: 35890089
PMC: 9318816.
DOI: 10.3390/ph15070789.
Paul A, Smith C, Rahmatullah M, Nissapatorn V, Wilairatana P, Spetea M
Pharmaceuticals (Basel). 2021; 14(11).
PMID: 34832873
PMC: 8620360.
DOI: 10.3390/ph14111091.
Henry S, Anand J, Brinkel A, McMillan D, Twarozynski J, Loo C
ACS Chem Neurosci. 2020; 12(1):216-233.
PMID: 33346631
PMC: 9923772.
DOI: 10.1021/acschemneuro.0c00693.
Brice-Tutt A, Senadheera S, Ganno M, Eans S, Khaliq T, Murray T
Molecules. 2020; 25(17).
PMID: 32887303
PMC: 7504817.
DOI: 10.3390/molecules25173999.
Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya R, Lei W, Ray A, Saini S, Zhang S, Molnar G
J Med Chem. 2020; 63(14):7663-7694.
PMID: 32530286
PMC: 9521336.
DOI: 10.1021/acs.jmedchem.0c00503.
Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
Henry S, Anand J, Twarozynski J, Brinkel A, Pogozheva I, Sears B
J Med Chem. 2020; 63(4):1671-1683.
PMID: 31986033
PMC: 7047604.
DOI: 10.1021/acs.jmedchem.9b01818.
Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show Kappa and Mu Opioid Receptor Agonism.
Montgomery D, Anand J, Griggs N, Fernandez T, Hartman J, Sanchez-Santiago A
ACS Chem Neurosci. 2019; 10(8):3682-3689.
PMID: 31199621
PMC: 6726392.
DOI: 10.1021/acschemneuro.9b00250.
Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
Henry S, Fernandez T, Anand J, Griggs N, Traynor J, Mosberg H
J Med Chem. 2019; 62(8):4142-4157.
PMID: 30924650
PMC: 6713576.
DOI: 10.1021/acs.jmedchem.9b00219.
Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design.
Nastase A, Anand J, Bender A, Montgomery D, Griggs N, Fernandez T
J Med Chem. 2019; 62(8):4193-4203.
PMID: 30916966
PMC: 7007966.
DOI: 10.1021/acs.jmedchem.9b00378.
Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
Nastase A, Griggs N, Anand J, Fernandez T, Harland A, Trask T
ACS Chem Neurosci. 2018; 9(7):1840-1848.
PMID: 29677442
PMC: 9976708.
DOI: 10.1021/acschemneuro.8b00139.
In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.
Dietis N, Niwa H, Tose R, McDonald J, Ruggieri V, Filaferro M
Br J Pharmacol. 2018; 175(14):2881-2896.
PMID: 29524334
PMC: 6016625.
DOI: 10.1111/bph.14199.
In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand J, Kochan K, Nastase A, Montgomery D, Griggs N, Traynor J
Br J Pharmacol. 2018; 175(11):2013-2027.
PMID: 29352503
PMC: 5978946.
DOI: 10.1111/bph.14148.
Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
Harland A, Pogozheva I, Griggs N, Trask T, Traynor J, Mosberg H
ACS Chem Neurosci. 2017; 8(11):2549-2557.
PMID: 28796483
PMC: 5691919.
DOI: 10.1021/acschemneuro.7b00284.
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.
Varadi A, Marrone G, Palmer T, Narayan A, Szabo M, Le Rouzic V
J Med Chem. 2016; 59(18):8381-97.
PMID: 27556704
PMC: 5344672.
DOI: 10.1021/acs.jmedchem.6b00748.
Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.
Harland A, Bender A, Griggs N, Gao C, Anand J, Pogozheva I
J Med Chem. 2016; 59(10):4985-98.
PMID: 27148755
PMC: 4885601.
DOI: 10.1021/acs.jmedchem.6b00308.
The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
Anand J, Boyer B, Mosberg H, Jutkiewicz E
Psychopharmacology (Berl). 2016; 233(13):2479-87.
PMID: 27117141
PMC: 5068912.
DOI: 10.1007/s00213-016-4296-8.
Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland A, Yeomans L, Griggs N, Anand J, Pogozheva I, Jutkiewicz E
J Med Chem. 2015; 58(22):8952-69.
PMID: 26524472
PMC: 4772774.
DOI: 10.1021/acs.jmedchem.5b01270.
Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender A, Griggs N, Anand J, Traynor J, Jutkiewicz E, Mosberg H
ACS Chem Neurosci. 2015; 6(8):1428-35.
PMID: 25938166
PMC: 4676711.
DOI: 10.1021/acschemneuro.5b00100.
Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
Beaudry H, Gendron L, Moron J
Eur J Neurosci. 2015; 41(7):901--7.
PMID: 25639561
PMC: 4390435.
DOI: 10.1111/ejn.12829.